16:10 EDT Jazz Pharmaceuticals (JAZZ) sees FY26 revenue $4.25B-$4.5B, consensus $4.45B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- JAZZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jazz Pharmaceuticals’ sBLA for Ziihera combination in GEA accepted by FDA
- Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays
- Nike downgraded, IBM initiated: Wall Street’s top analyst calls
- Jazz Pharmaceuticals resumed with an Outperform at Raymond James